title: Management of ACCF/AHA Stage C heart failure.
abstract: ACC Stage C heart failure includes those patients with prior or current symptoms of heart failure in the context of an underlying structural heart problem who are primarily managed with medical therapy. Although there is guideline-based medical therapy for those with heart failure with reduced ejection fraction (HFrEF), therapies in heart failure with preserved ejection fraction (HFpEF) have thus far proven elusive. Emerging therapies such as serelaxin are currently under investigation and may prove beneficial. The role of advanced surgical therapies, such as mechanical circulatory support, in this population is not well defined. Further investigation is warranted for these therapies in patients with Stage C heart failure.
authors.affiliation: Mechanical Circulatory Support & Heart Transplantation Program, Ahmanson-UCLA Cardiomyopathy Center, David Geffen School of Medicine, University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 630 East, Los Angeles, CA 90095, USA.
authors.forename: Sasikanth
authors.initials: S
authors.lastname: Adigopula
authors.forename: Rey P
authors.initials: RP
authors.lastname: Vivo
authors.forename: Eugene C
authors.initials: EC
authors.lastname: DePasquale
authors.forename: Ali
authors.initials: A
authors.lastname: Nsair
authors.forename: Mario C
authors.initials: MC
authors.lastname: Deng
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D058406:Cardiac Resynchronization Therapy / Q000379:methods; D002316:Cardiotonic Agents / Q000627:therapeutic use; D001026:Coronary Artery Bypass / Q000379:methods; D017147:Defibrillators, Implantable; D004039:Diet, Sodium-Restricted; D004077:Digoxin / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005081:Exercise Therapy / Q000379:methods; D006333:Heart Failure / Q000209:etiology / Q000628:therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000601:surgery; D009765:Obesity / Q000150:complications; D010349:Patient Compliance; D010353:Patient Education as Topic; D020181:Sleep Apnea, Obstructive / Q000150:complications; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D014665:Vasodilator Agents; D004077:Digoxin
keywords: Drug therapy; Heart failure; Stage C; Surgical treatment